Why Dr Martens’ shares stomped higher despite first half loss
Recent trading 'encouraging'Cost savings at top of guidanceInventory and net debt downHard-pressed footwear company Dr Martens (DOCS) lurched into loss for the half ended 29 September 2024 as higher costs and a slump in wholesale revenue, notably in the US, took a heavy toll on its performance.Yet despite this swing into the red, shares in the boots, shoes and sandals seller rallied 15% to 67p aft